2023-11-14 10:22:24 ET
More on RenovoRx
- Seeking Alpha’s Quant Rating on RenovoRx
- Historical earnings data for RenovoRx
- Financial information for RenovoRx
For further details see:
RenovoRx GAAP EPS of -$0.132023-11-14 10:22:24 ET
For further details see:
RenovoRx GAAP EPS of -$0.13Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
LOS ALTOS, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today annou...
LOS ALTOS, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced t...
LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced t...